Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study

Authors:

Abstract
No abstract available
Funding Information
  • QIMR Berghofer Medical Research Institute
  • National Health and Medical Research Council
  • Medicines for Malaria Venture

This publication has 19 references indexed in Scilit: